Selecta Biosciences (SELB) Deep Dive Reveals Investors Should Focus on Catalysts - Cantor Fitzgerald

March 3, 2021 7:03 AM EST
Get Alerts SELB Hot Sheet
Price: $3.84 +4.92%

Rating Summary:
    7 Buy, 2 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 20 | Down: 24 | New: 32
Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Cantor Fitzgerald analyst Eliana Merle reiterated an Overweight rating and $10.00 price target on Selecta Biosciences (NASDAQ: SELB) after doing a deep dive on the company resulting in a 65 page analysis that concludes 2020 was a year of validating the potential of the ImmTOR platform through the COMPARE study and extensive preclinical work. Looking ahead, investors should focus on the near term catalysts in 2021 related to ImmTOR for GTs since the ImmTOR platform offers significant advantages that will address many of the key limitations of GT.

The analyst stated "Pipeline Could Lead to Significant Near- and Long-Term Inflection Points. We think investors should focus on SELB's growing pipeline, which also includes multiple GTs (in house and through collaborations/partnerships), IgA nephropathy, and primary biliary
cholangitis (PBC)." She went on to state "ImmTOR has demonstrated key advantages on safety and efficacy. This includes recent NHP data showing a first dose benefit of higher/more durable transgene expression (potentially through increased trafficking to the liver). Importantly, recent literature suggests the effects are from the addition of ImmTOR."

For an analyst ratings summary and ratings history on Selecta Biosciences click here. For more ratings news on Selecta Biosciences click here.

Shares of Selecta Biosciences closed at $4.22 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

Cantor Fitzgerald